Health Care & Life Sciences » Biotechnology | Aquinox Pharmaceuticals Inc.

Aquinox Pharmaceuticals Inc. | Ownership

Companies that own Aquinox Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Baker Bros. Advisors LP
10,934,154
46.6%
0
0.22%
06/30/2018
Ecor1 Capital LLC
1,758,973
7.5%
608,973
0.56%
07/05/2018
T. Rowe Price Associates, Inc.
1,350,000
5.75%
-2,384,999
0%
06/30/2018
Prosight Management LP
400,900
1.71%
400,900
0.86%
06/30/2018
DLD Asset Management LP
379,900
1.62%
379,900
0.15%
06/30/2018
The Vanguard Group, Inc.
328,559
1.4%
18,204
0%
06/30/2018
BlackRock Fund Advisors
307,706
1.31%
2,011
0%
06/30/2018
Highbridge Capital Management LLC
288,618
1.23%
288,618
0.03%
06/30/2018
Sphera Funds Management Ltd.
257,613
1.1%
182,078
0.12%
06/30/2018
University of Notre Dame (Investment Management)
214,759
0.92%
76,891
0.12%
06/30/2018

About Aquinox Pharmaceuticals

View Profile
Address
887 Great Northern Way
Vancouver British Columbia V5T 4T5
Canada
Employees -
Website http://www.aqxpharma.com
Updated 07/08/2019
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.